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Use of antibiotics and asthma medication
for acute lower respiratory tract infections
in people with and without asthma:
retrospective cohort study
Rachel Denholm1* , Esther T. van der Werf1,2 and Alastair D. Hay1
Abstract
Background: Antibiotics are overused in patients with acute lower respiratory tract infections (ALRTIs), but less is
known about their use in patients with asthma, or the use of asthma medication for ALRTI in patients without
asthma. Our aim was to describe the frequency, variation and drivers in antibiotic and asthma medication
prescribing for ALRTI in adults with and without asthma in primary care.
Methods: A retrospective cohort analysis of patients aged ≥12 years, diagnosed with an ALRTI in primary care in
2014–15 was conducted using data from the Clinical Practice Research Datalink. Current asthma status, asthma
medication and oral antibiotic use within 3 days of ALRTI infection was determined. Treatment frequency was
calculated by asthma status. Mixed-effect regression models were used to explore between-practice variation and
treatment determinants.
Results: There were 127,976 ALRTIs reported among 110,418 patients during the study period, of whom 17,952
(16%) had asthma. Respectively, 81 and 79% of patients with and without asthma received antibiotics, and 41 and
15% asthma medication. There were significant differences in between-practice prescribing for all treatments, with
greatest differences seen for oral steroids (odds ratio (OR) 18; 95% CI 7–82 and OR = 94; 33–363, with and without
asthma) and asthma medication only (OR 7; 4–18 and OR = 17; 10–33, with and without asthma).
Independent predictors of antibiotic prescribing among patients with asthma included fewer previous ALRTI
presentations (≥2 vs. 0 previous ALRTI: OR = 0.25; 0.16–0.39), higher practice (OR = 1.47; 1.35–1.60 per SD) and prior
antibiotic prescribing (3+ vs. 1 prescriptions OR = 1.28; 1.04–1.57) and concurrent asthma medication (OR = 1.44;
1.32–1.57). Independent predictors of asthma medication in patients without asthma included higher prior asthma
medication prescribing (≥7 vs. 0 prescriptions OR = 2.31; 1.83–2.91) and concurrent antibiotic prescribing (OR = 3.59;
3.22–4.01).
Conclusion: Findings from the study indicate that antibiotics are over-used for ALRTI, irrespective of asthma status,
and asthma medication is over-used in patients without asthma, with between-practice variation suggesting
considerable clinical uncertainty. Further research is urgently needed to clarify the role of these medications for
ALRTI.
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Background
Acute lower respiratory tract infections (ALRTI) is one
of the most common acute illnesses managed in primary
care, and accounts for between 8 and 10% of all primary
care antibiotic prescribing [1]. In the UK, 63–70% of
ALRTIs presenting at primary care are treated with anti-
biotics [2], despite good evidence they do not effectively
reduce symptom duration or severity [3]. Prescribing un-
necessary antibiotics not only contributes to a financial
burden on health services, but also to antimicrobial
resistance [4].
Asthma is one of the most common chronic diseases in
the UK. For patients with existing asthma, ALRTIs can
have a profound effect on the expression of disease. Vi-
ruses, most frequently Rhinovirus, are the predominant
microorganisms associated with infective asthma exacer-
bations [5, 6]. The British Thoracic Society guidelines
state that treatment of acute asthma exacerbations, even
when infection is considered the trigger, should be ste-
roids, and not antibiotics [7]. A recent Cochrane review
found that using antibiotics for asthma exacerbation
showed no reduction in symptoms [8]. However, the guid-
ance on the management of ALRTIs in patients with
asthma in primary care, with or without asthma exacerba-
tion, remains unclear. Indeed, using clinical tools currently
available it is not possible to establish if there is infection,
inflammation or both present in these patients. Studies in
children indicate that the simultaneous prescribing of an-
tibiotics and asthma medications for respiratory tract in-
fections is extremely common [9–11], but this has not
been described in adults with asthma.
National antimicrobial resistance action plans aim
to reduce the over-prescription and use of antibiotics.
Recently, an increase in prescribing of asthma medi-
cation (including oral steroids) for patients without
asthma has been reported [12, 13], despite good
evidence that these are an ineffective treatment for
ALRTI in these patients [14, 15].
In the UK, little has been published on the treatment
of ALRTI by asthma status. The aim of the study was to
describe the frequency and variation of antibiotic and
asthma medication prescribing following a diagnosis for
ALRTI, and investigate factors associated with prescrib-
ing among patients with and without asthma, using
electronic health records in England.
Method
Study population
This was a retrospective cohort study using routinely
collected, anonymised, primary care electronic health re-
cords of over 5 million active patients from around 650
UK general practices from the Clinical Practice Research
Datalink (CPRD), considered representative of the gen-
eral UK population [16]. The database includes the
diagnostic codes used in routine clinical practice and all
prescriptions. Approval was granted by the CPRD
Independent Scientific Advisory Committee (protocol
reference 16_290).
ALRTIs were identified using diagnostic codes for
ALRTI (Additional file 1: Appendix 1) in patients aged
12 to 80 years presenting between 1 January 2014 and 31
December 2015. Patients aged < 12 years were excluded
due to difficulties of reliably diagnosing asthma [17]. We
also excluded patients for whom antibiotics were consid-
ered appropriate according to NICE guidelines, includ-
ing those with chronic lung diseases other than asthma,
e.g. chronic obstructive pulmonary disease [17]. The in-
fection episode was the unit of analysis, thus a patient
diagnosed with ≥1 ALRTI episode within the study
period was included multiple times. Repeat recordings of
ALRTI within 28 days were assumed to be a single epi-
sode, with the index date defined by the first code.
Measurements
Current asthma status at ALRTI diagnosis was de-
fined as ever having a recorded asthma diagnosis (in-
cluding an asthma exacerbation code) and prescribed
an asthma medication in the previous 12 months
(Additional file 1: Appendices 2 and 3). Treatment
for ALRTI was defined as a prescription for an orally
administered antibiotic or a change in asthma medi-
cation prescribing within 3 days of diagnosis. Antibiotics
included those most commonly used for ALRTI [18]: doxy-
cycline, amoxicillin, clarithromycin, azithromycin, co-
amoxiclav, erythromycin, tetracycline, cefalexin, and cefra-
dine. A change in asthma medication was defined as an in-
crease in dose, and/or an additional asthma medication
prescribed, in relation to the previous month, for those with
asthma, and a prescription for any asthma medication in
patients without asthma.
Gender and age at first ALRTI diagnosis were calcu-
lated, and patients index of multiple deprivation (IMD)
categorised by quintiles. Smoking status was ascertained
using READ codes, and categorised as never, ex- and
current smokers [19]. Season of infection was cate-
gorised as winter (1st January – 31st March 2014, 1st
October 2014 – 31st March 2015, and 1st October –
31st December 2015) and summer. Number of ALRTI
diagnoses, and all antibiotic (British National Formulary
[BNF] chapter 5.1) and asthma medication (Additional
file 1: Appendix 3) prescriptions in the 12months prior
to ALRTI diagnosis were derived.
A list of 37 physical and mental long-term conditions
(Additional file 1: Appendix 4) established by clinical
consensus were used to ascertain comorbidity status [20,
21]. A simple, unweighted count of clinical conditions
was derived, and a four-category measure, grouping 0, 1,
2, and ≥ 3 conditions created.
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Number of ALRTI episodes prescribed an antibiotic
per 1000 population per year, using practice list size at
the beginning of the study period, was calculated.
Statistical analysis
Descriptive analysis was used to investigate differences
in demographic and clinical factors, and ALRTI treat-
ment, by asthma status. Variation in prescribing patterns
(percentage of patients) across practices was explored
using a mixed-effects model. The random effect for
practice in a model with no covariates represents the un-
measured variation between practices.
Multi-level logistic regression models were fitted to
investigate patient, clinical and practice factors associ-
ated with being prescribed an antibiotic or asthma
medication for an ALRTI. Odd ratios (ORs) and 95%
confidence intervals (CIs) were calculated. Univariate
analysis of each variable was conducted, and measures
with a p-value ≥0.25 were included in multivariate
analysis (hereafter called the full model). Models were
conducted in patients with and without asthma,
separately.
Covariates were included as fixed effects, with a
random intercept term for general practice allowing
for within-practice comparisons. Thus, OR represents
changes in odds of prescribing when covariates differ
within the same practice. Age and practice ALRTI
antibiotic rates were standardised using respective
sample mean values and standard deviations (SD),
and all continuous measurements were grouped into
relevant categories, or quartiles. Non-linear associa-
tions were investigated in the full model, and the
most appropriate, as determined using likelihood ratio
tests, are presented.
Data analysis was conducted using STATA version 14
software [22]. All tests of significance were two-sided.
Sensitivity analysis
To assess whether our asthma status definition affected
prescribing estimates, particularly the use of asthma
medication in patients without asthma, analyses were re-
peated using increasingly stringent definitions of non-
asthma (previous asthma but no treatment within the
last 5 years; and never having an asthma diagnosis). To
evaluate whether the use of asthma medication in pa-
tients without asthma was an indication of an underlying
asthma or COPD diagnosis, we repeated descriptive ana-
lysis excluding those with an asthma or COPD diagnosis
code within a year of an infection. Finally, to assess
whether patients with multiple infections influenced
study findings, analyses were restricted to patients first
infection during the study period. IMD was not available
for 47.5% (n = 60,839) of ALRTI episodes, thus models
were repeated without IMD, and findings compared.
Results
During the study period, 127,976 ALRTIs were reported
among 110,418 patients, of whom 17,952 (16.3%) had
asthma (Table 1). Nearly all antibiotic and asthma medi-
cation (99.9%) were prescribed on the day of ALRTI
diagnosis.
Antibiotics were prescribed for nearly 80% of ALR-
TIs in both groups (Table 2), with amoxicillin and
clarithromycin being the most common (70.6 and
13.3% of antibiotics prescribed, respectively). Asthma
medication was prescribed in 41.1 and 14.7% of epi-
sodes (27 and 7% oral steroids) in patients with and
without asthma, respectively. Among patients without
asthma, salbutamol and prednisolone were the most
commonly prescribed asthma medications (66.8 and
44.6% of asthma medications prescribed, respectively).
For the majority (90.5%) of ALRTI episodes pre-
scribed an asthma medication, patients were also
given an antibiotic.
There was variation in the frequency of antibiotic and
asthma medication prescribing across practices (Table 2).
Overall, practices who prescribed antibiotics most fre-
quently (97.5 percentile of antibiotics prescribing) were
twice as likely to prescribe an antibiotic, compared to
those who prescribed the least (2.5% percentile); odds
ratio (OR) 1.92 (95% CI 1.69–2.26, p < 0.001) and 2.20
(1.92–2.58, p < 0.001) for patients with and without
asthma, respectively. Practices at the top of the 95%
mid-range of practices (i.e. 97.5th percentile compared
to 2.5th percentile of asthma medication prescribing)
had almost eight-times and 17-times the odds of pre-
scribing an asthma medication only, compared to prac-
tices at the bottom, in patients with and without asthma,
respectively.
Predictors of antibiotic prescribing
In the full models, one of the strongest independent
predictor of an antibiotic prescription, irrespective of
asthma status, was the number of prior antibiotic pre-
scriptions for any clinical indication: patients with 3
or more, compared to 1, prior antibiotic prescriptions
were more likely to receive an antibiotic prescription;
OR 1.28 (95% CI 1.04–1.57, p < 0.001) and 1.34
(1.21–1.49, p < 0.001) and in patients with and with-
out asthma, respectively (Tables 3 and 4). A higher
number of previous ALRTIs was inversely associated
with antibiotic prescribing (≥2 vs. 0: 0.25; 0.16–0.39,
p < 0.001; and 0.16; 0.13–0.20, p < 0.001, for patients
with and without asthma, respectively), whilst increas-
ing practice ALRTI antibiotic prescribing was posi-
tively associated with antibiotic prescribing (1.47;
1.35–1.60, p < 0.001; and 1.45; 1.39–1.52, p < 0.001
per SD for patients with and without asthma, respect-
ively). Females were less likely to have an antibiotic
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Table 1 Demographic and clinical characteristics of patients with at least one ALRTIa in 2014–15, stratified by asthma statusb
Patients with asthma Patients without asthma P-value
Demographic factors
Number of patients 17,952 (16.3) 92,466 (83.74)
Gender, n (%) Male 6391 (35.6) 38,509 (42.0)
Female 11,560 (64.4) 53,995 (58.4) < 0.001
Age at ALRTI (years) Mean (SD) 49.1 (17.3) 50.1 (17.3) < 0.001
IMD quintile, n (%) 1 (Least) 1909 (20.5) 10,699 (21.8)
2 1862 (20.0) 10,133 (20.6)
3 1876 (20.2) 9746 (19.8)
4 1805 (19.4) 9164 (18.7)
5 (Most) 1849 (19.9) 9403 (19.1) 0.02
Smoking status, n (%) Never smoker 6971 (38.8) 36,596 (39.6)
Smoker 7973 (44.4) 43,989 (47.6)
Previous 3008 (16.8) 11,875 (12.8) < 0.001
Clinical factors
Number of infections, n 20,990 (16.4) 106,986 (83.6)
Season of infection Summer 39,315 (36.8) 7648 (36.4)
Winter 67,671 (63.3) 13,342 (63.6) 0.39
Number (%) of ALRTI in prior 12 months Mean (SD) 0.2 (0.5) 0.2 (0.5) < 0.001
0 17,737 (84.5) 93,279 (87.2)
1 2535 (12.1) 10,820 (10.1)
2+ 718 (3.4) 2887 (2.7) < 0.001
Multimorbidity score at index infectionc, n (%) Mean (SD) 1.7 (1.7) 1.4 (1.6) < 0.001
0 7003 (33.4) 43,529 (40.7)
1 4803 (22.9) 24,257 (22.7)
2 3484 (16.6) 16,575 (15.5)
3+ 5700 (27.2) 22,625 (21.2) < 0.001
Number (%) of asthma medications prescribed in previous 12 monthsd, Mean (SD) 8.2 (8.5) 0.5 (2.5) < 0.001
0 – 101,210 (94.6)
1–6 11,797 (56.2) 5010 (4.7)
7+ 9193 (43.8) 766 (0.7) < 0.001
Number (%) of antibiotics prescribed in previous 12 monthse Mean (SD) 2.5 (2.8) 1.7 (2.0) < 0.001
0 2807 (13.4) 17,734 (16.6)
1 6471 (30.8) 48,091 (45)
2 4461 (21.3) 20,852 (19.5)
3+ 7251 (34.6) 20,309 (19) < 0.001
Practice factors
Practice ALRTI antibiotic prescribingf, per 1000 patients Mean (SD) 801.6 (67.1) 798.0 (68.0) < 0.001
SD Standard deviation, IQR Inter-quartile range, IMD Index multiple deprivation
Table 1 presents information from all ALRTI episodes. Demographic factor statistics are for patients (n = 110,418). Clinical factor statistics are for ALRTI episodes
(n = 127,976). P-values report Pearson chi-squared test for independence for categorical variables and t-tests for equality of means for continuous measures.
a Acute lower respiratory tract infection;
b Asthma defined as ever diagnosed and prescribed an asthma medication in the 12months prior to date of ALRTI
c A list of 36 physical and mental chronic conditions (excluding asthma) were used to ascertain multimorbidity status in participants at ALRTI diagnosis [20, 23]
d Asthma medication includes long- and short-acting β2 agonists, leukotriene receptor antagonists, antimuscarinic bronchodilators, and inhaled and
oral corticosteroids
e Any antibiotics (BNF chapter 5.1) prescribed in the last 12 months for any condition
f Antibiotic prescribed within 3 days of a ALRTI diagnosis
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prescription for an ALRTI, compared to males; 0.75
(0.63–0.90, p < 0.001) and 0.82 (0.76–0.88, p < 0.001),
with and without asthma, respectively.
Among patients with asthma, a concurrent change in
asthma medication and IMD quintile, previous smoking
status and multimorbidity (Table 4), were also positively
associated with receiving an antibiotic. Age and season
of infection were not independently associated with an
antibiotic prescription. Smoking status and multimorbid-
ity in patients with asthma (Table 3), and IMD quintile
and asthma medication in patients without asthma
(Table 4) were not independently associated with an
antibiotic prescription.
Predictors of asthma medication prescribing
In the full models (Tables 5 and 6), a corresponding anti-
biotic prescription was the strongest independent pre-
dictor of a change in asthma medication (5.22; 4.54–6.01,
p < 0.001 and 3.59; 3.22–4.01, p < 0.001 for patients with
and without asthma, respectively). Prior prescriptions for
asthma medication were also positively associated with a
prescription; patients with asthma 2–4 vs. 1 prescription
1.14; 1.01–1.29, p < 0.001; and patients without asthma ≥7
vs. 0 prescriptions 2.31; 1.83–2.91, p < 0.001). Other
predictors of being prescribed an asthma medication in-
cluded a positive association with current smoking status,
inverse relationship with age and number of prior ALRTI,
and mixed (with asthma) and positive (without asthma)
association with multimorbidity.
Among patients without asthma, females, compared to
males, were more likely to receive a prescription for
asthma medication (Table 5).
IMD quintile and season of infection were not associ-
ated with an asthma medication prescription. Among
those with asthma, gender was not associated with a
change in asthma medication (Table 6).
Sensitivity analysis
Overall, broadening our asthma definition status made lit-
tle difference to general prescribing trends across groups
(Additional file 1: Appendix 5). Among patients ever diag-
nosed with asthma, 73.5% of ALRTI episodes were pre-
scribed an antibiotic (compared to 81.5% in the main
analysis) and 33.9% had a change in asthma medication
(compared to 41.1%). Among those who had never had an
asthma diagnosis, 82.4 and 12.3% of ALRTI episodes were
prescribed an antibiotic and asthma medication, respect-
ively (compared to 79.3 and 14.7%, respectively in the
Table 2 Episode and measures of practice variance in medication prescribed within 3 days of ALRTIa diagnosis, stratified by asthmab
status
Patients with asthma Patients without asthma
ALRTI episodes, n = 127,976 (n, %)
No treatment 3374 (16.1) 20,293 (19.0)
Antibiotics onlyc 8985 (42.8) 70,944 (66.3)
d Asthma medication only 508 (2.4) 1803 (1.7)
Oral steroide 298 (1.4) 808 (0.8)
Antibioticsc and asthma medicationd 8123 (38.7) 13,946 (13.0)
Antibioticsc and oral steroidse 5341 (25.4) 6318 (5.9)
Practice variance, n = 513 (95% mid-range OR, 95% CI) f
No treatment 3.09 (2.41, 4.23) 2.04 (1.81, 2.36)
Antibiotics onlyc 1.63 (1.46, 1.88) 1.89 (1.72, 2.13)
Asthma medication onlyd 7.46 (4.00, 18.46) 17.18 (10.08, 33.1)
Oral steroide 17.76 (6.55, 81.91) 93.92 (33.15, 362.72)
Antibioticsc and asthma medicationd 1.62 (1.45, 1.87) 2.46 (2.14, 2.91)
Antibioticsc and oral steroidse 2.94 (2.37, 3.84) 5.81 (4.39, 8.11)
IQR Interquartile range
a Acute lower respiratory tract infection
b Defined as ever diagnosed and asthma medication prescribed in the 12 months prior to ALRTI
c Antibiotics limited to oral formulations and includes amoxicillin, doxycycline, clarithromycin, co-amoxiclav, azithromycin, erythromycin, tetracycline,
cefalexin, cefradine
d Among patients without asthma, asthma medication refers to any asthma medication, including oral corticosteroids. Among patients with asthma, asthma
medication refers to an increase in the dose of current treatment and/or additional asthma medication (including oral corticosteroids) prescribed compared to the
prior month
e Oral steroids refer to oral corticosteroids
f Practice variance was calculated from the variance of the random effect (σ2) and is given by e2 × 1.96 × σ and represents the odds ratio comparing a practice at
the 2.5th percentile of the distribution of practices to one at the 97.5th percentile for the treatment outcome of interest. For example, amongst patients without
asthma, practices who most frequently prescribed no treatment were 2.14 times more likely to prescribe no treatment compared to practices who prescribed no
treatment the least
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Univariate analysis Full model
OR (95% CI) p-value OR (95% CI) p-value
2052 (18.9) 8787 (81.1)
Demographic factors
Gender Male 652 (31.8) 3127 (35.6) 1 (ref) 1 (ref)
Female 1400 (68.2) 5659 (64.4) 0.84 (0.76, 0.94) < 0.001 0.75 (0.63, 0.90) 0.002
Age at ALRTI (years) c per SD 0.94 (0.89, 0.99) 0.01 1.02 (0.93, 1.12) 0.64
IMD quintile 1 (Least) 390 (19.0) 1765 (20.1) 1 (ref) 1 (ref)
2 363 (17.7) 1774 (20.2) 1.09 (0.92, 1.29) 1.27 (0.99, 1.65)
3 418 (20.4) 1733 (19.7) 0.94 (0.79, 1.11) 1.33 (1.02, 1.72)
4 424 (20.7) 1723 (19.6) 0.91 (0.76, 1.08) 1.26 (0.97, 1.64)
5 (Most) 457 (22.3) 1792 (20.4) 0.89 (0.74, 1.06) 0.17 1.52 (1.15, 1.99) 0.05
Current smoking status Never 826 (40.3) 3415 (38.9) 1 (ref) 1 (ref)
Current 1007 (49.1) 3857 (43.9) 0.93 (0.83, 1.03) 1.04 (0.87, 1.25)
Previous 219 (10.7) 1515 (17.2) 1.71 (1.45, 2.02) < 0.001 0.94 (0.74, 1.19) 0.69
Clinical factors
Season of infection Summer 786 (38.3) 3113 (35.4) 1 (ref) 1 (ref)
Winder 1266 (61.7) 5674 (64.6) 1.13 (1.02, 1.25) 0.02 1.14 (0.96, 1.34) 0.13
Prescribed asthma medication d No 1758 (85.7) 4600 (52.4) 1 (ref) 1 (ref)
Yes 294 (14.3) 4187 (47.7) 5.76 (5.04, 6.59) < 0.001 1.44 (1.32, 1.57) < 0.001
Number of ALRTI in prior 12 months 0 1214 (59.2) 7932 (90.3) 1 (ref) 1 (ref)
1 592 (28.9) 727 (8.3) 0.18 (0.16, 0.21) 0.52 (0.41, 0.67)
2+ 246 (12.0) 128 (1.5) 0.07 (0.06, 0.09) < 0.001 0.25 (0.17, 0.39) < 0.001
Multimorbidity score e 0 1135 (55.3) 2518 (28.7) 1 (ref) 1 (ref)
1 307 (15.0) 2279 (25.9) 3.34 (2.89, 3.85) 1.13 (0.90, 1.41)
2 221 (10.8) 1592 (18.1) 3.29 (2.80, 3.87) 1.35 (1.04, 1.76)
3+ 389 (19.0) 2398 (27.3) 2.85 (2.49, 3.25) < 0.001 1.05 (0.83, 1.33) 0.12
Number of antibiotics prescribed
in previous 12 months f




1 600 (10.7) 7094 (33.5) 1 (ref) 1 (ref)
2 333 (6.0) 5290 (25.0) 1.26 (1.01, 1.57) 1.31 (1.05, 1.64)
3+ 620 (11.1) 8705 (41.1) 1.06 (0.88, 1.28) < 0.001 1.28 (1.04, 1.57) < 0.001
Practice factors
Practice ALRTI antibiotic rates (per 1000 patients)
c
per SD 1.55 (1.46, 1.64) < 0.001 1.47 (1.35, 1.59) < 0.001
OR Odds ratio, CI Confidence interval, SD Standard deviation, ref reference
Model restricted to participants with complete information on all variables included in the full model. Multi-level logistic regression models were used, with
general practice included as a random effect to account for clustering. Coefficients represent the odds of receiving an antibiotic for a unit increase in the
exposure of interest. Antibiotics prescribed within 3 days of ALRTI, and includes amoxicillin, doxycycline, clarithromycin, co-amoxiclav, azithromycin, erythromycin,
tetracycline, cefalexin, and cefradine
a Acute lower respiratory tract infection
b Defined as ever diagnosed and asthma medication prescribed in the 12 months prior to ALRTI
c Age at index infection and practice ALRTI antibiotic rates standardised (using sample mean values and SDs), and coefficients represent a change in the OR in
antibiotic prescribing per 1-standard deviation increment in exposure of interest
d Asthma medication refers to an increase in the dose of current treatment and/or additional asthma medication prescribed compared to the prior month for
patients with asthma. Asthma medication includes long- and short-acting β2 agonists, leukotriene receptor antagonists, antimuscarinic bronchodilators, and
inhaled and oral corticosteroids
e A list of 37 physical and mental chronic conditions were used to ascertain multimorbidity status in participants at ALRTI diagnosis
f Any antibiotics (BNF chapter 5.1) prescribed in the last 12 months for any condition
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main analysis). Likewise, excluding patients without
asthma who were diagnosed with asthma or COPD within
a year of an index infection had little impact on the
results. Asthma medications were prescribed for 14.3% of
patients without asthma in sensitivity analysis, compared
to 14.7% in the main analysis (data not shown).






Univariate analysis Full model
OR (95% CI) p-value OR (95% CI) p-value
11,592 (20.1) 44,706 (79.4)
Demographic factors
Gender Male 4339 (37.4) 18,589 (41.6) 1 (ref) 1 (ref)
Female 7253 (62.6) 26,117 (58.4) 0.84 (0.81, 0.88) < 0.001 0.82 (0.76, 0.88) < 0.001
Age at ALRTI (years) c per SD 0.90 (0.88, 0.92) < 0.001 1.00 (0.96, 1.04) 0.87
IMD quintile 1 (Least) 2202 (19.0) 9737 (21.8) 1 (ref) 1 (ref)
2 2164 (18.7) 9275 (20.8) 0.95 (0.88, 1.02) 0.99 (0.88, 1.12)
3 2257 (19.5) 8824 (19.7) 0.87 (0.81, 0.94) 0.94 (0.83, 1.05)
4 2341 (20.2) 8321 (18.6) 0.79 (0.73, 0.85) 0.90 (0.80, 1.01)
5 (Most) 2628 (22.7) 8549 (19.1) 0.75 (0.69, 0.81) < 0.001 1.01 (0.89, 1.15) 0.21
Smoking status Never 4363 (37.6) 17,652 (39.5) 1 (ref) 1 (ref)
Current 6220 (53.7) 20,966 (46.9) 0.84 (0.81, 0.88) 1.00 (0.93, 1.08)
Previous 1009 (8.7) 6085 (13.6) 1.51 (1.40, 1.63) < 0.001 1.19 (1.05, 1.34) 0.01
Clinical factors
Season of infection Summer 4391 (37.9) 15,994 (35.8) 1 (ref) 1 (ref)
Winder 7201 (62.1) 28,712 (64.2) 1.10 (1.05, 1.15) < 0.001 1.06 (0.98, 1.14) 0.14
Prescribed asthma medication d No 10,548 (91.0) 37,436 (83.7) 1 (ref) 1 (ref)
Yes 1044 (9.0) 7270 (16.3) 2.11 (1.97, 2.27) < 0.001 1.04 (0.94, 1.15) 0.43
Number of ALRTI in prior 12 months 0 7440 (64.2) 42,027 (94.0) 1 (ref) 1 (ref)
1 3131 (27.0) 2318 (5.2) 0.13 (0.12, 0.14) 0.24 (0.21, 0.27)
2+ 1021 (8.8) 361 (0.8) 0.06 (0.05, 0.07) < 0.001 0.16 (0.13, 0.20) < 0.001
Multimorbidity score e 0 6998 (60.4) 16,143 (36.1) 1 (ref) 1 (ref)
1 1626 (14.0) 11,484 (25.7) 3.14 (2.96, 3.33) 1.15 (1.05, 1.27)
2 1176 (10.1) 7513 (16.8) 2.87 (2.68, 3.08) 1.09 (0.97, 1.21)
3+ 1792 (15.5) 9566 (21.4) 2.45 (2.31, 2.60) < 0.001 0.96 (0.86, 1.07) < 0.001
Number of antibiotics prescribed
in previous 12 months f
0 8636 (74.5) 532 (1.2) 0.004 (0.003, 0.004) 0.006 (0.005, 0.006)
1 1584 (13.7) 24,577 (55.0) 1 (ref) 1 (ref)
2 659 (5.7) 10,163 (22.7) 0.99 (0.90, 1.09) 1.16 (1.05, 1.28)
3+ 713 (6.2) 9434 (21.1) 0.86 (0.78, 0.94) < 0.001 1.35 (1.21, 1.49) < 0.001
Practice factors
Practice ALRTI antibiotic rates
(per 1000 patients) c
per SD 1.47 (1.44, 1.5) < 0.001 1.45 (1.39, 1.52) < 0.001
OR Odds ratio, CI Confidence interval, SD Standard deviation, ref reference
Models restricted to participants with complete information on all variables included in the full model. Multi-level logistic regression models were used, with
general practice included as a random effect to account for clustering. Coefficients represent the odds of receiving antibiotic prescription for a unit increase in the
exposure of interest. Antibiotics prescribed within 3 days of ALRTI, and includes amoxicillin, doxycycline, clarithromycin, co-amoxiclav, azithromycin, erythromycin,
tetracycline, cefalexin, and cefradine
a Acute lower respiratory tract infection
b Defined as ever diagnosed and asthma medication prescribed in the 12 months prior to ALRTI
c Age at index infection and practice ALRTI antibiotic rates standardised (using sample mean values and SDs), and coefficients represent a change in the OR in
antibiotic prescribing per 1-standard deviation increment in exposure of interest
d Asthma medication refers to a prescription for any asthma medication. Asthma medication includes long- and short-acting β2 agonists, leukotriene receptor
antagonists, antimuscarinic bronchodilators, and inhaled and oral corticosteroids
e A list of 37 physical and mental chronic conditions were used to ascertain multimorbidity status in participants at ALRTI diagnosis
f Any antibiotics (BNF chapter 5.1) prescribed in the last 12 months for any condition
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To assess the influence of multiple infections, sensitiv-
ity analysis restricted to the first ALRTI episode was per-
formed (Additional file 1: Appendix 6). Prior antibiotic
prescribing for any clinical indication was not positively
associated with antibiotic prescribing in sensitivity ana-
lysis, due to more patients having an antibiotic prescrip-
tion in the prior 12 months for later infection episodes,
compared to the first ALRTI episode, especially for those
prescribed antibiotics (51.5% vs. 18.3%). Unlike in the
main analysis, where an inverse relationship was ob-
served between number of prior ALRTIs and antibiotics
in patients with asthma, and asthma medication in pa-
tients without asthma, no relationship was found in the
sensitivity analysis.
No differences were observed in models where IMD
was excluded (data not shown).
Discussion
Summary
The main findings from this investigation of routine
health records in a patient population at low-risk of
pneumonia suggest that antibiotics were frequently pre-
scribed for ALRTIs irrespective of asthma status, in con-
trast to NICE recommendations [24]. Changes to
asthma medication prescriptions was observed in only
41% of ALRTI episodes in patients with asthma, but
higher than expected levels were found in patients with-
out asthma at 15%, with 40% of these including oral cor-
ticosteroids. Asthma medication was infrequently
prescribed without antibiotics. The considerable vari-
ation in prescribing across practices, especially for
asthma medication, highlights the clinical uncertainty in
treating ALRTI. Factors associated with prescribing of
both antibiotics and asthma medication were broadly
similar irrespective of asthma status, with the strongest
factors relating to the frequency of previous ALRTI epi-
sodes and treatment.
Strengths and limitations
To our knowledge, this is the first study to use routine
medical records to investigate antibiotic and asthma
medication use for ALRTIs by asthma status in patients
at low risk of pneumonia. The prescribing data are reli-
able since electronic prescribing is ubiquitous in UK pri-
mary care, and similarly, the coding of factors placing
patients at high risk of pneumonia, and most patient
demographics are reliably coded.
Despite these strengths, there are limitations. First, the
relationship between ALRTI, and antibiotic and asthma
medication prescribing, is temporal. Although likely to
be linked, in some cases medication could have been
prescribed for other reasons. However, most medications
were prescribed on the day of ALRTI diagnosis. Second,
CPRD is a database of electronic medical records, and
coding quality may influence study findings, particularly
diagnostic codes, with a clinicians decision to record a
diagnosis potentially linked to prescribing choices [25].
However, we used a broad range of clinical codes to de-
fine and capture ALRTIs and findings of high-levels of
antibiotic use are in keeping with previous general popu-
lation studies that have used clinical inclusion criteria
[26, 27]. Third, clinician’s often advice patients with
asthma to increase the dose of existing asthma medica-
tions, and thus an analysis based on a change in pre-
scription will probably under-estimate a change in use of
asthma medication. Finally, our definition of asthma
may mean some patients with a diagnosis of asthma will
be in the non-asthma group potentially leading to an
over-estimation of asthma medication in this population.
Clinicians who suspect asthma or COPD may also be
more likely to prescribe an asthma medication without
clinically diagnosing or reporting. However, we used a
standard method which has been shown to accurately
reflect asthma status in CPRD [28], and explored
broader definitions and excluded patients later diag-
nosed with asthma and COPD in sensitivity analysis.
Furthermore, the prevalence of asthma was comparable
to the UK lifetime prevalence in a large, linked database
study (16.3% vs. 15.6%) [29].
Comparisons with existing literature
Our finding of high levels of antibiotic prescribing for
ALRTI in primary care are consistent with the estab-
lished literature [27, 30, 31]. Results indicate that
there is little difference in prescribing of antibiotics
by asthma status, despite guidance that they should
be avoided [24], and evidence that they are not effect-
ive in treating ALRTI [8]. There has been little inves-
tigation of antibiotic prescribing for ALRTI in adults
with asthma, although the available evidence indicates
that antibiotics are still frequently prescribed for
asthma exacerbations [32, 33].
Antibiotic prescribing was associated with patients’
prior patterns of antibiotic prescribing, although when
analysis was restricted to the first ALRTI episode, this
association was attenuated in patients with asthma and
reversed in those without. Results indicate that prior
prescribing influences the likelihood of being prescribed
an antibiotic for subsequent presentations, with infre-
quent prescribing in patients not prescribed antibiotics
in the recent past. Prescribing practices are likely to be
influenced by doctor and practice characteristics as well
as patient expectations, as shown in other studies [34,
35]. Practice ALRTI prescribing was positively associated
with antibiotic use, comparable to an earlier analysis of
UK primary care data [30].
A surprising finding was the negative association be-
tween antibiotic prescribing and frequent ALRTI episodes
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in the patients recent past. This may be due to characteris-
tics associated with frequent attenders, or indicate GPs re-
luctance to provide an antibiotic prescription multiple
times for the same indication. Indeed, of those patients
diagnosed with two or more ALRTI episodes (3605), two-
thirds (65.6%) had not had an antibiotic prescription in
the same period, compared to 10.5% of patients who had
not had a prior ALRTI episode, suggesting clinicians were





Univariate analysis Full model
OR (95% CI) p-value OR (95% CI) p-value
6358 (58.7) 4481 (41.3)
Demographic factors
Gender Male 2187 (34.4) 1592 (35.5) 1 (ref)
Female 4170 (65.6) 2889 (64.5) 0.95 (0.87, 1.03) 0.21
Age at ALRTI (years) Q1 (< 39) 1477 (23.2) 1219 (27.2) 1 (ref) 1 (ref)
Q2 (39-) 1534 (24.1) 1198 (26.7) 0.93 (0.84, 1.04) 0.97 (0.87, 1.09)
Q3 (52-) 1620 (25.5) 1055 (23.5) 0.77 (0.69, 0.87) 0.85 (0.75, 0.96)
Q4 (64+) 1727 (27.2) 1009 (22.5) 0.70 (0.62, 0.78) < 0.001 0.75 (0.66, 0.85) < 0.001
IMD quintile 1 (Least) 1249 (19.6) 906 (20.2) 1 (ref)
2 1277 (20.1) 860 (19.2) 0.94 (0.83, 1.07)
3 1215 (19.1) 936 (20.9) 1.06 (0.93, 1.21)
4 1271 (20.0) 876 (19.6) 0.95 (0.83, 1.09)
5 (Most) 1346 (21.2) 903 (20.2) 0.95 (0.82, 1.09) 0.31
Smoking status Never 2539 (39.9) 1702 (38.0) 1 (ref) 1 (ref)
Current 2815 (44.3) 2049 (45.7) 1.09 (1.00, 1.19) 1.13 (1.03, 1.24)
Previous 1004 (15.8) 730 (16.3) 1.09 (0.97, 1.22) 0.13 1.04 (0.92, 1.17) 0.03
Clinical factors
Season of infection Summer 2261 (35.6) 1638 (36.6) 1 (ref)
Winder 4097 (64.4) 2843 (63.5) 0.96 (0.89, 1.04) 0.37
Prescribed an antibiotic c No 1758 (27.7) 294 (6.6) 1 (ref) 1 (ref)
Yes 4600 (72.4) 4187 (93.4) 5.69 (4.98, 6.50) < 0.001 5.22 (4.54, 6.01) < 0.001
Number of ALRTI in prior 12 months 0 5114 (80.4) 4032 (90.0) 1 (ref) 1 (ref)
1 935 (14.7) 384 (8.6) 0.53 (0.46, 0.60) 0.81 (0.71, 0.93)
2+ 309 (4.9) 65 (1.5) 0.27 (0.21, 0.36) < 0.001 0.57 (0.42, 0.76) < 0.001
Multimorbidity score d 0 2249 (35.4) 1404 (31.3) 1 (ref) 1 (ref)
1 1386 (21.8) 1200 (26.8) 1.38 (1.25, 1.53) 1.10 (0.98, 1.22)
2 1017 (16.0) 796 (17.8) 1.25 (1.11, 1.40) 1.03 (0.90, 1.16)
3+ 1706 (26.8) 1081 (24.1) 1.00 (0.90, 1.11) < 0.001 0.88 (0.78, 0.99) < 0.001
Number of asthma medications
prescribed in previous 12 months
Q1 (1) 1158 (18.2) 700 (15.6) 1 (ref) 1 (ref)
Q2 (2-) 2057 (32.4) 1691 (37.7) 1.35 (1.20, 1.51) 1.14 (1.01, 1.29)
Q3 (5-) 1406 (22.1) 1014 (22.6) 1.18 (1.04, 1.34) 1.03 (0.90, 1.17)
Q4 (11+) 1737 (27.3) 1076 (24.0) 1.01 (0.90, 1.15) < 0.001 0.96 (0.84, 1.09) 0.01
OR odds ratio; CI confidence interval; ref reference; Q quartile
Models restricted to participants with complete information on all variables included in the full model. Multi-level logistic regression models were used, with
general practice included as a random effect to account for clustering. Coefficients represent the odds of receiving asthma medication for a unit increase in the
exposure of interest. IMD quintile and gender were excluded from the analysis as the model did not converge. Asthma medication refers to a an increase in the
dose of current treatment and/or additional asthma medication prescribed compared to the prior month. Asthma medication includes long- and short-acting β2
agonists, leukotriene receptor antagonists, antimuscarinic bronchodilators, and inhaled and oral corticosteroids
a Acute lower respiratory tract infection
b Defined as ever diagnosed and asthma medication prescribed in the 12 months prior to ALRTI
c Antibiotics prescribed within 3 days of ALRTI, and includes amoxicillin, doxycycline, clarithromycin, co-amoxiclav, azithromycin, erythromycin, tetracycline,
cefalexin, and cefradine
d A list of 37 physical and mental chronic conditions were used to ascertain multimorbidity status in participants at ALRTI diagnosis
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more likely to prescribe antibiotics to patients who don’t
often present, perhaps because they had a more severe
illness. A further unexpected result was the inverse cor-
relation between multimorbidity score and an antibiotic
prescription in patients without asthma, and a change in
asthma medication among patients with asthma. Patients
with multiple chronic conditions are seen more frequently
by the GP and therefore, clinicians may be more inclined
to delay prescribing. Age was also inversely associated
with an asthma medication, indicating clinicians were less
likely to increase the dose of asthma medication for
elderly, multimorbid patients.
Asthma medication was used frequently, irrespective
of asthma status, and commonly alongside an antibiotic.
International studies have also found antibiotics and cor-
ticosteroids are commonly co-prescribed for asthma ex-
acerbations [32], and in patients without asthma [36,
37]. Indeed, here, an antibiotic prescription was one of





Univariate analysis Full model
OR (95% CI) p-value OR (95% CI) p-value
47,984 (85.2) 8314 (14.8)
Demographic factors
Gender Male 19,910 (41.5) 3018 (36.3) 1 (ref) 1 (ref)
Female 28,074 (58.5) 5296 (63.7) 1.25 (1.19, 1.31) < 0.001 1.10 (1.03, 1.18) 0.01
Age at ALRTI (years) Q1 (< 39) 11,264 (23.5) 2377 (28.6) 1 (ref) 1 (ref)
Q2 (39-) 11,815 (24.6) 2319 (27.9) 0.92 (0.87, 0.99) 1.02 (0.93, 1.12)
Q3 (52-) 12,583 (26.2) 2067 (24.9) 0.78 (0.73, 0.83) 0.81 (0.73, 0.89)
Q4 (64+) 12,322 (25.7) 1551 (18.7) 0.60 (0.56, 0.65) < 0.001 0.59 (0.53, 0.66) < 0.001
IMD quintile 1 (Least) 10,272 (21.4) 1667 (20.1) 1 (ref) 1 (ref)
2 9856 (20.5) 1583 (19.0) 0.98 (0.91, 1.07) 0.92 (0.82, 1.03)
3 9371 (19.5) 1710 (20.6) 1.08 (0.99, 1.17) 1.03 (0.91, 1.15)
4 9027 (18.8) 1635 (19.7) 1.12 (1.03, 1.23) 0.94 (0.84, 1.07)
5 (Most) 9458 (19.7) 1719 (20.7) 1.20 (1.09, 1.32) < 0.001 0.97 (0.86, 1.11) 0.31
Smoking status Never 19,115 (39.8) 2900 (34.9) 1 (ref) 1 (ref)
Current 22,726 (47.4) 4460 (53.7) 1.30 (1.23, 1.36) 1.10 (1.02, 1.19)
Previous 6141 (12.8) 953 (11.5) 1.02 (0.94, 1.10) < 0.001 1.00 (0.89, 1.12) 0.02
Clinical factors
Season of infection Summer 17,348 (36.2) 3037 (36.5) 1 (ref)
Winter 30,636 (63.9) 5277 (63.5) 0.98 (0.93, 1.03) 0.47
Prescribed an oral antibiotic c No 10,548 (22.0) 1044 (12.6) 1 (ref) 1 (ref)
Yes 37,436 (78.0) 7270 (87.4) 2.11 (1.97, 2.27) 3.59 (3.22, 4.01)
Number of ALRTI in prior 12 months, per ALRTI 0.85 (0.81, 0.90) < 0.001 0.89 (0.83, 0.97) 0.01
Multimorbidity score d 0 20,119 (41.9) 3022 (36.4) 1 (ref) 1 (ref)
1 10,960 (22.8) 2150 (25.9) 1.30 (1.22, 1.38) 1.15 (1.05, 1.26)
2 7328 (15.3) 1361 (16.4) 1.25 (1.16, 1.34) 1.07 (0.96, 1.19)
3+ 9577 (20.0) 1781 (21.4) 1.24 (1.16, 1.32) < 0.001 1.08 (0.98, 1.19) 0.02
Number of asthma medications prescribed
in previous 12 months
0 13,486 (86.6) 3813 (80.2) 1 (ref) 1 (ref)
1–6 1867 (12) 808 (17.0) 1.50 (1.37, 1.65) 1.57 (1.43, 1.73)
7+ 221 (1.4) 131 (2.8) 2.18 (1.74, 2.74) < 0.001 2.31 (1.83, 2.91) < 0.001
OR odds ratio; CI confidence interval; ref reference; Q quartile
Models restricted to participants with complete information on all variables included in the full model. Multi-level logistic regression models were used, with
general practice included as a random effect to account for clustering. Coefficients represent the odds of receiving asthma medication for a unit increase in the
exposure of interest. Asthma medication refers to any asthma medication, including long- and short-acting β2 agonists, leukotriene receptor antagonists,
antimuscarinic bronchodilators, and inhaled and oral corticosteroids
a Acute lower respiratory tract infection
b Defined as ever diagnosed and asthma medication prescribed in the 12 months prior to ALRTI
c Antibiotics prescribed within 3 days of ALRTI, and includes amoxicillin, doxycycline, clarithromycin, co-amoxiclav, azithromycin, erythromycin, tetracycline,
cefalexin, and cefradine
d A list of 37 physical and mental chronic conditions were used to ascertain multimorbidity status in participants at ALRTI diagnosis
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the strongest predictors of being prescribed an asthma
medication.
Implications for research and/or practice
Our study provides evidence that general practices are
continuing to frequently prescribe antibiotics for ALRTI,
despite evidence of limited benefit, and in contradiction to
national guidelines. Furthermore, practitioners frequently
co-prescribe asthma medication and antibiotics, which
may reflect uncertainty regarding the underlying aetiology.
High quality research has been conducted to determine
the lack of effectiveness of antibiotics in ALRTI in a non-
asthmatic low-risk patient population [3] and in reducing
symptoms of asthma exacerbations [8], but research is
now needed to address the clinical uncertainty in the
optimum management of ALRTI in patients with asthma.
Conclusion
We have demonstrated high-use of antibiotics and
asthma medication for the treatment of ALRTI in
patients with and without asthma, respectively, with con-
siderable between-practice variation. Further research is
urgently needed to inform optimum use of both antibi-
otics and asthma medication for patients with ALRTI.
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